Amendments to the Claims

1. (Original) A compound represented by the formula (I)

wherein

R¹ is a lower alkyl substituted by a lower alkoxy or a heterocyclic group, or a heterocyclic group;

R² is a lower alkyl optionally substituted by a phenyl; and

R³ is hydrogen, a lower alkyl optionally substituted by a halogen, a lower alkoxy or a phenyl, or a fused polycyclic hydrocarbon group.

2. (Original) The compound as claimed in Claim 1, wherein the lower alkyl represented by R¹ which is substituted by a lower alkoxy is a group of the formula (IIa)

$$R^4 - \left(O - R^5\right)_m \qquad (IIa)$$

in which R⁴ is a lower alkyl, R⁵ is a lower alkylene, and m is an integer of 1 to 6.

3. (Original) The compound as claimed in Claim 1, wherein the lower alkyl represented by R^1 which is substituted by a lower alkoxy is a group of the formula (IIb)

$$H_3C - \left(O - CH_2CH_2\right)_n$$
 ([]b)

in which n is an integer of 1 to 6.

- **4. (Original)** The compound as claimed in Claim 1, wherein the heterocyclic group which is a substituent for the lower alkyl represented by R¹ is pyridyl optionally having a lower alkyl.
- **5.** (Original) The compound as claimed in Claim 1, wherein the hetero atom of the heterocyclic group represented by R¹ is an oxygen atom.
- 6. (Currently amended) The compound as claimed in any one of Claims 1 to 5

 Claim 1, wherein the lower alkyl represented by R³ is cyclopropyl.
- **7. (Original)** ((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 2-methoxyethyl ester,
- ((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester,
- ((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 8-methoxy-3,6-dioxaoctyl ester,
- ((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 11-methoxy-3,6,9-trioxaundecanyl ester, or
- ((1S)-1-((((1S)-1-benzyl-3-(cyclopropylamino)-2,3-dioxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 2-(pyridin-2-yl)ethyl ester.
- 8. (Currently amended) A medicament comprising the compound as claimed in Claim 1-or Claim 7.
- 9. (Original) The medicament as claimed in Claim 8, which is a calpain inhibitor.
- 10. (Original) The medicament as claimed in Claim 9, which is a prophylactic and/or therapeutic agent for a disease related to calpain.

- 11. (Original) The medicament as claimed in Claim 10, wherein the disease related to calpain is ischemic disease, immunologic disease, multiple sclerosis, Alzheimer's disease, osteoporosis, diseases caused by brain tissue damage, cataract, glaucoma, retinal disease, retinochoroiditis, posterior eyeball complications due to photocoagulation or a disease involving neovascularization.
- **12.** (New) The compound as claimed in Claim 2, wherein the lower alkyl represented by R³ is cyclopropyl.
- 13. (New) The compound as claimed in Claim 3, wherein the lower alkyl represented by R³ is cyclopropyl.
- 14. (New) The compound as claimed in Claim 4, wherein the lower alkyl represented by R³ is cyclopropyl.
- 15. (New) The compound as claimed in Claim 5, wherein the lower alkyl represented by R³ is cyclopropyl.
- **16.** (New) A medicament comprising the compound as claimed in Claim 7.
- 17. (New) The medicament as claimed in Claim 16, which is a calpain inhibitor.
- **18.** (New) The medicament as claimed in Claim 17, which is a prophylactic and/or therapeutic agent for a disease related to calpain.
- 19. (New) The medicament as claimed in Claim 18, wherein the disease related to calpain is ischemic disease, immunologic disease, multiple sclerosis, Alzheimer's disease, osteoporosis, diseases caused by brain tissue damage, cataract, glaucoma, retinal disease, retinochoroiditis, posterior eyeball complications due to photocoagulation or a disease involving neovascularization.